Related Experiment Video
Updated: Feb 22, 2026
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
8.3K
Drug development against tuberculosis: Past, present and future.
Mahesh S Vasava1, Manoj N Bhoi1, Sanjay K Rathwa1
1Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India.
The Indian Journal of Tuberculosis
|September 25, 2017
Summary
Tuberculosis (TB) treatment faces challenges from drug resistance. New drugs like bedaquiline and delamanid offer hope, with more novel candidates in development for resistant Mycobacterium tuberculosis strains.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis, caused by Mycobacterium tuberculosis (MTB), is an ancient human pathogen with significant global morbidity and mortality, particularly in resource-limited settings.
- Current treatments for drug-resistant tuberculosis (TB) are lengthy, have severe side effects, and poor outcomes, exacerbated by emerging extensively drug-resistant (XDR-TB) and totally drug-resistant (TDR-TB) strains.
- The emergence of multi-drug resistant tuberculosis (MDR-TB) and XDR-TB strains significantly hampers global TB control efforts, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review existing and emerging treatments for tuberculosis, focusing on novel methodologies for drug-resistant strains.
- To summarize new anti-tuberculosis drug candidates with novel mechanisms of action currently in clinical trials or preclinical development.
- To provide an overview of the shifting treatment landscape for sensitive and resistant Mycobacterium tuberculosis infections.
Main Methods:
- Literature review of existing and pipeline anti-tuberculosis drugs.
- Analysis of recent clinical trial data and preclinical development for novel TB drug candidates.
- Summary of approved drugs and compounds with promising activity against sensitive and resistant MTB.
Main Results:
- Several new anti-tuberculosis drug candidates with novel modes of action are in clinical trials, showing promise against resistant strains.
- Recent FDA approvals of bedaquiline and delamanid mark a shift in the TB treatment landscape.
- A robust pipeline of compounds in clinical and preclinical development demonstrates promising activity against both sensitive and resistant Mycobacterium tuberculosis.
Conclusions:
- Novel therapeutic agents are crucial for combating drug-resistant tuberculosis (TB).
- The development pipeline for new TB drugs is expanding, offering improved efficacy and safety profiles.
- The reviewed existing and emerging treatments provide a comprehensive overview for managing sensitive and resistant Mycobacterium tuberculosis infections.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis II
1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
01:28Pulmonary Tuberculosis V
663
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
663
01:26Pulmonary Tuberculosis IV
560
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
560
01:29Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
01:31Pulmonary Tuberculosis III
1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
01:28Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K